Treatment Centers and Clinical Trials
You can restrict your search to only Treatment Centers or only Clinical Trials by checking the Treatment Center or Clinical Trial checkbox under TYPE. Use the Zoom-In (+ sign on the lower right of the map) to enlarge the map area to find your preferred location. To search for a Treatment Center or Clinical Trial, click on the red map pin for the name of the facility. Click on the name of the facility for more details.
Location
Treatments/Services
Type
ROCHESTER SKIN LYMPHOMA MEDICAL GROUP, PLLC
Rush University Medical Center
The University of Kansas Hospital
The Warren Alpert Medical School of Brown University, Department of Dermatology
Seattle Cancer Care Alliance
Tulane University School of Medicine
University Dermatology Consultants, Inc.
University Hospitals of Cleveland
University of Alabama Medical Center
University of California, San Francisco
University of Iowa Hospitals & Clinics
University of North Carolina Medical Center
University of Pittsburgh Medical Center
University of Rochester - Wilmot Cancer Institute
University of Texas Southwestern Medical Center
University of Virginia-Emily Couric Clinical Cancer Center
University of Wisconsin - Madison
Vanderbilt University Medical Center
Wake Forest Baptist Health
Winship Cancer Institute - Emory University
Mayo Clinic - Arizona Campus
Cleveland Clinic
Clinical Cancer Center, Froedtert Hospital
Saint Louis University Cancer Center
Washington University Medical Center - Siteman Cancer Center
The Dermatology Clinic at University of Minnesota
Henry Ford Medical Center - Cutaneous T-cell Lymphoma Clinic
University of Michigan Medical Center
Northwestern Medicine
University of Chicago
Yale University School of Medicine
Penn Cutaneous Lymphoma Program
Jefferson Cutaneous Lymphoma Clinic
Boston Medical Center - Cutaneous Oncology Program
Center for Cutaneous Oncology at Dana Farber/Brigham and Women's Cancer Center
Beth Israel Medical Center
Massachusetts General Hospital Cancer Center
Virginia Commonwealth University Medical Center
INOVA Melanoma and Skin Oncology Center
Dartmouth-Hitchcock Norris Cotton Cancer Center
Columbia University Irving Medical Center - Cutaneous Lymphoma Center
NYU Grossman School of Medicine
University of Texas MD Anderson Cancer Center
Moffitt Cancer Center
Cleveland Clinic - Indian River Hospital
Miami Cancer Institute BHSF
Levine Cancer Institute
Duke Cutaneous T-Cell Lymphoma Clinic and Research Center
UCHealth - University of Colorado Cancer Center - Anschutz
Huntsman Cancer Institute
Stanford Medical Center (Multidisciplinary Cutaneous Lymphoma Clinic)
Oregon Health & Science University (OHSU)
GW Cancer Center
Medical University of South Carolina
John Hopkins Dermatology
OU Physicians
City of Hope National Medical Center
Chao Family Comprehensive Cancer Center
Peter MacCallum Cancer Centre
Westmead Hospital - University of Sydney
Medical University of Graz
Medical University of Vienna
Hôtel-Dieu - CHU de Nantes
Helsinki University Hospital
Hospital Dresden-Friedrichstadt
Charité University of Medicine Berlin - Skin Cancer Center
Skin Cancer Center - HELIOS Klinikum Krefeld
Rabin Medical Center
Rambam Medical Center
Spedali Civili di Brescia
Cutaneous Lymphoma Multidisciplinary Clinic - Lisbon
Friedrich Schiller University - Hospital Jena
University Medical Centre - Mannheim
University of Essen - Department of Dermatology
Semmelweis Medical School
Hospital Universitario 12 de Octubre
University Hospital Zurich - Department of Dermatology
Memorial Sloan Kettering Cancer Center
John Theurer Cencer Center at HUMC
Emil P. Bisaccia, MD, Center for Photopheresis at Morristown Medical Center
Johann Wolfgang Goethe-University Frankfurt
OSU Comprehensive Cancer Center
Roswell Park Comprehensive Cancer Center
St. Thomas Hospital - St Johns Department of Dermatology
Leflunomide for CD30+
Lacutamab - TELLOMAK Study
An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of lacutamab (IPH4102) alone or in combination with chemotherapy in patients with advanced t-cell lymphoma
Clinical Trial Name: IPH4102-201 / TELLOMAK study
Clinical Trial Description:
Naloxone Hydrochloride - Study
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Purpose
TTI-621 - Study
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Brief Summary
Multicenter, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.